Maria Thor1, Caroline E Olsson2, Jung Hun Oh1, Stine E Petersen3, David Alsadius4, Lise Bentzen3, Niclas Pettersson5, Ludvig P Muren3, Ann-Charlotte Waldenström2, Morten Høyer3, Gunnar Steineck2, Joseph O Deasy1. 1. a Department of Medical Physics , Memorial Sloan Kettering Cancer Center , New York , USA. 2. b Division of Clinical Cancer Epidemiology, Department of Oncology , Institute of Clinical Sciences, the Sahlgrenska Academy at the University of Gothenburg , Sweden. 3. c Departments of Medical Physics and Oncology , Aarhus University Hospital , Aarhus , Denmark. 4. d Oncology, University of Gothenburg , Gothenburg , Sweden. 5. e Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital , Gothenburg , Sweden.
Abstract
BACKGROUND: Gastrointestinal (GI) morbidity after radiotherapy (RT) for prostate cancer is typically addressed by studying specific single symptoms. The aim of this study was to explore the interplay between domains of patient- reported outcomes (PROs) on GI morbidity, and to what extent these are explained by RT dose to the GI tract. MATERIAL AND METHODS: The study included men from two Scandinavian studies (N = 211/277) who had undergone primary external beam radiotherapy (EBRT) for localized prostate cancer to 70-78 Gy (2 Gy/fraction). Factor analysis was applied to previously identified PRO-based symptom domains from two study-specific questionnaires. Number of questions: 43; median time to follow-up: 3.6-6.4 years) and dose-response outcome variables were defined from these domains. Dose/volume parameters of the anal sphincter (AS) or the rectum were tested as predictors for each outcome variable using logistic regression with 10-fold cross-validation. Performance was assessed using area under the receiver operating characteristic curve (Az) and model frequency. RESULTS: Outcome variables from Defecation urgency (number of symptoms: 2-3), Fecal leakage (4-6), Mucous (4), and Pain (3-6) were defined. In both cohorts, intermediate rectal doses predicted Defecation urgency (mean Az: 0.53-0.54; Frequency: 70-75%), and near minimum and low AS doses predicted Fecal leakage (mean Az: 0.63-0.67; Frequency: 83-99%). In one cohort, high AS doses predicted Mucous (mean Az: 0.54; Frequency: 96%), whereas in the other, low AS doses and intermediate rectal doses predicted Pain (mean Az: 0.69; Frequency: 28-82%). CONCLUSION: We have demonstrated that Defecation urgency, Fecal leakage, Mucous, and Pain following primary EBRT for localized prostate cancer primarily are predicted by intermediate rectal doses, low AS doses, high AS doses, or a combination of low AS and intermediate rectal doses, respectively. This suggests that there is a domain-specific dose-response for the GI tract. To reduce risk of GI morbidity, dose distributions of both the AS region and the rectum should, therefore, be considered when prescribing prostate cancer RT.
BACKGROUND: Gastrointestinal (GI) morbidity after radiotherapy (RT) for prostate cancer is typically addressed by studying specific single symptoms. The aim of this study was to explore the interplay between domains of patient- reported outcomes (PROs) on GI morbidity, and to what extent these are explained by RT dose to the GI tract. MATERIAL AND METHODS: The study included men from two Scandinavian studies (N = 211/277) who had undergone primary external beam radiotherapy (EBRT) for localized prostate cancer to 70-78 Gy (2 Gy/fraction). Factor analysis was applied to previously identified PRO-based symptom domains from two study-specific questionnaires. Number of questions: 43; median time to follow-up: 3.6-6.4 years) and dose-response outcome variables were defined from these domains. Dose/volume parameters of the anal sphincter (AS) or the rectum were tested as predictors for each outcome variable using logistic regression with 10-fold cross-validation. Performance was assessed using area under the receiver operating characteristic curve (Az) and model frequency. RESULTS: Outcome variables from Defecation urgency (number of symptoms: 2-3), Fecal leakage (4-6), Mucous (4), and Pain (3-6) were defined. In both cohorts, intermediate rectal doses predicted Defecation urgency (mean Az: 0.53-0.54; Frequency: 70-75%), and near minimum and low AS doses predicted Fecal leakage (mean Az: 0.63-0.67; Frequency: 83-99%). In one cohort, high AS doses predicted Mucous (mean Az: 0.54; Frequency: 96%), whereas in the other, low AS doses and intermediate rectal doses predicted Pain (mean Az: 0.69; Frequency: 28-82%). CONCLUSION: We have demonstrated that Defecation urgency, Fecal leakage, Mucous, and Pain following primary EBRT for localized prostate cancer primarily are predicted by intermediate rectal doses, low AS doses, high AS doses, or a combination of low AS and intermediate rectal doses, respectively. This suggests that there is a domain-specific dose-response for the GI tract. To reduce risk of GI morbidity, dose distributions of both the AS region and the rectum should, therefore, be considered when prescribing prostate cancer RT.
Authors: Florian Buettner; Sarah L Gulliford; Steve Webb; Matthew R Sydes; David P Dearnaley; Mike Partridge Journal: Radiother Oncol Date: 2012-04-18 Impact factor: 6.280
Authors: Gilles Defraene; Laura Van den Bergh; Abrahim Al-Mamgani; Karin Haustermans; Wilma Heemsbergen; Frank Van den Heuvel; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-12 Impact factor: 7.038
Authors: Sarah L Gulliford; Mike Partridge; Matthew R Sydes; Steve Webb; Philip M Evans; David P Dearnaley Journal: Radiother Oncol Date: 2011-11-25 Impact factor: 6.280
Authors: Martin A Ebert; Kerwyn Foo; Annette Haworth; Sarah L Gulliford; Angel Kennedy; David J Joseph; James W Denham Journal: Int J Radiat Oncol Biol Phys Date: 2015-01-13 Impact factor: 7.038
Authors: Peter Chang; Konrad M Szymanski; Rodney L Dunn; Jonathan J Chipman; Mark S Litwin; Paul L Nguyen; Christopher J Sweeney; Robert Cook; Andrew A Wagner; William C DeWolf; Glenn J Bubley; Renee Funches; Joseph A Aronovitz; John T Wei; Martin G Sanda Journal: J Urol Date: 2011-07-23 Impact factor: 7.450
Authors: Robert Jan Smeenk; Wim P M Hopman; Aswin L Hoffmann; Emile N J Th van Lin; Johannes H A M Kaanders Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: Maria Thor; Caroline E Olsson; Jung Hun Oh; David Alsadius; Niclas Pettersson; Joseph O Deasy; Gunnar Steineck Journal: J Sex Med Date: 2015-11-13 Impact factor: 3.802
Authors: Maria Thor; Caroline Olsson; Jung Hun Oh; Stine Elleberg Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig Paul Muren; Morten Høyer; Gunnar Steineck; Joseph O Deasy Journal: Radiother Oncol Date: 2016-02-12 Impact factor: 6.280
Authors: M Thor; C E Olsson; J H Oh; J Hedström; N Pauli; M Johansson; J O Deasy; C Finizia Journal: Clin Otolaryngol Date: 2017-05-29 Impact factor: 2.597
Authors: Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor Journal: Acta Oncol Date: 2017-09-08 Impact factor: 4.089
Authors: Douglas H Brand; Sarah C Brüningk; Anna Wilkins; Katie Fernandez; Olivia Naismith; Annie Gao; Isabel Syndikus; David P Dearnaley; Alison C Tree; Nicholas van As; Emma Hall; Sarah Gulliford Journal: Int J Radiat Oncol Biol Phys Date: 2021-01-04 Impact factor: 7.038
Authors: Paul Sargos; Mame Daro Faye; Manon Bacci; Stéphane Supiot; Igor Latorzeff; David Azria; Tamim M Niazi; Te Vuong; Véronique Vendrely; Renaud de Crevoisier Journal: Front Oncol Date: 2021-06-16 Impact factor: 6.244